Neuroprotection in Huntington Disease
- 274 Downloads
Huntington’s disease (HD) is an autosomal dominant hereditary disorder characterized by chorea (excessive, spontaneous, irregularly timed abrupt movements), disturbed voluntary motor performance, behavioral changes and dementia. Functional capacity slowly declines as a result of increasing motor and cognitive deficits until the patient becomes bedridden. The course is progressive, with death usually occurring 15–20 years after disease onset. Death is most frequently caused by aspiration pneumonia.
- Di Pardo A, Amico E, Favellato M, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Mol Genet 2014;23:2251–2265.Google Scholar
- Jain KK. Fingolimod. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019.Google Scholar
- Jain KK. Pramipexole. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019a.Google Scholar
- Luis-Ravelo D, Estévez-Silva H, Barroso-Chinea P, et al. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington’s disease. Exp Neurol 2019;299(Pt A):137–147.Google Scholar
- Miguez A, García Díaz-Barriga G, Brito V, et al. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington’s disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Mol Genet 2015;24:4948–57.Google Scholar